Download PDF
Aktuelle Neurologie 2013; 40(06): 327-332
DOI: 10.1055/s-0033-1349432
Workshop
© Georg Thieme Verlag KG Stuttgart · New York

Parkinson-Syndrom(e) – Neue Konzepte für eine sich ausbreitende Erkrankung?

Parkinson Syndrome(s) – New Concepts for a Spreading Disease?
J. Klucken
1   Molekulare Neurologie, Universitätsklinikum Erlangen
,
B. Herting
2   Klinik für Neurologie und Gerontoneurologie, Diakonie-Klinikum Schwäbisch Hall
,
R. Hilker
3   Klinik für Neurologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt
,
J. B. Schulz
4   Neurologische Klinik, Universitätsklinikum der RWTH Aachen
,
P. Vieregge
5   Klinik für Neurologie, Klinikum Lippe-Lemgo GmbH
,
D. Woitalla
6   Neurologische Klinik, Universitätsklinikum der Ruhr-Universität Bochum
,
M. Wolz
7   Klinik für Neurologie, Elblandklinikum Meißen
,
H. Reichmann
8   Klinik und Poliklinik für Neurologie, Carl Gustav Carus Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
14 August 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neueste Erkenntnisse über den klinischen Verlauf, die Pathologie und die zellbiologischen Konzepte der Parkinson-Syndrome legen eine kontinuierliche Ausbreitung sowohl von Symptomen als auch der zugrunde liegenden Schädigung des Nervensystems nahe. Diese Konzepte ändern den Blickwinkel, aus dem die Parkinson-Syndrome aus ärztlicher, neuropathologischer und zellbiologischer Sicht betrachtet werden. Dies hat Konsequenzen für die diagnostische Zuordnung und bietet neue therapeutische Optionen. In diesem Artikel werden diese neuen Sichtweisen zusammengefasst, und die entstehenden Kontroversen diskutiert. Der Ausblick veranschaulicht daraus resultierende erste Ansätze für neue therapeutische Strategien.

Abstract

The latest knowledge about the clinical course, pathology, and cell biological concepts in Parkinson’s disease suggest a continuous spreading of both the symptoms and the underlying degeneration of the nervous system. These new concepts influence the point-of-view of physicians, pathologists, and cell biologists: they have a substantial impact on the diagnostic classification and the development of novel therapeutic options. The present article outlines the new viewpoints and controversies, and summarises the resulting scientific concepts to develop therapeutic strategies.

Schlüsselwörter

Parkinson-Syndrome - Zell-zu-Zell-Propagation - Krankheitsverlauf

Keywords

Parkinson syndrome - cell-to-cell propagation - course of the disease
 

  • Literatur

  • 1 Oertel WH, Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener HC, Putzki H, Hrsg. Leitlinien der Deutschen Gesellschaft für Neurologie. Stuttgart: Georg Thieme Verlag; 2008
    Google Scholar
  • 2 Clarke G, Lumsden CJ, McInnes RR. Inherited neurodegenerative diseases: the one-hit model of neurodegeneration. Hum Mol Genet 2001; 10: 2269-2275
    CrossrefPubMedGoogle Scholar
  • 3 Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991: 1-14
    CrossrefPubMedGoogle Scholar
  • 4 Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord 2011; 26: 1049-1055
    CrossrefPubMedGoogle Scholar
  • 5 Malkus KA, Tsika E, Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 2009; 4: 24
    CrossrefPubMedGoogle Scholar
  • 6 Khoo TK, Yarnall AJ, Duncan GW et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013; 80: 276-281
    CrossrefPubMedGoogle Scholar
  • 7 Riedel O, Heuser I, Klotsche J et al. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. J Geriatr Psychiatry Neurol 2010; 23: 27-34
    CrossrefPubMedGoogle Scholar
  • 8 Zahodne LB, Marsiske M, Okun MS et al. Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol 2012; 25: 131-137
    CrossrefPubMedGoogle Scholar
  • 9 Doty RL. Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis 2012; 46: 527-552
    CrossrefPubMedGoogle Scholar
  • 10 Berardelli A, Wenning GK, Antonini A et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 2013; 20: 16-34
    CrossrefPubMedGoogle Scholar
  • 11 Shults CW. Lewy bodies. Proc Natl Acad Sci U S A 2006; 103: 1661-1668
    CrossrefPubMedGoogle Scholar
  • 12 Saito Y, Ruberu NN, Sawabe M et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 2004; 63: 742-749
    PubMedGoogle Scholar
  • 13 Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003; 18 (Suppl. 06) S2-12
    PubMedGoogle Scholar
  • 14 Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 1998; 3: 462-465
    CrossrefPubMedGoogle Scholar
  • 15 Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson’s disease. Parkinsons Dis 2011; 2011: 708404
    PubMedGoogle Scholar
  • 16 Kupsky WJ, Grimes MM, Sweeting J et al. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37: 1253-1255
    CrossrefPubMedGoogle Scholar
  • 17 Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 1997; 38 (Suppl. 02) 2-7
    PubMedGoogle Scholar
  • 18 Rajput AH, Rozdilsky B. Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry 1976; 39: 1092-1100
    CrossrefPubMedGoogle Scholar
  • 19 Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol 2008; 15 (Suppl. 01) 14-20
    CrossrefPubMedGoogle Scholar
  • 20 Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and definitions. Mov Disord 2012; 27: 608-616
    CrossrefPubMedGoogle Scholar
  • 21 Noyce AJ, Bestwick JP, Silveira-Moriyama L et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012; 72: 893-901
    CrossrefPubMedGoogle Scholar
  • 22 Walter U, Klucken J, Benecke R et al. Brain Sonography, Olfactory and Motor Function Assessment for the Early Diagnosis of Idiopathic Parkinson’s Disease. Akt Neurol 2012; 39: 127-134
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Winkler J, Ehret R, Buttner T et al. Parkinson’s disease risk score: moving to a premotor diagnosis. J Neurol 2011; 258 (Suppl. 02) S311-S315
    PubMedGoogle Scholar
  • 24 Stiasny-Kolster K, Doerr Y, Moller JC et al. Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128: 126-137
    Google Scholar
  • 25 Jost WH, Eckardt VF. Constipation in idiopathic Parkinson’s disease. Scand J Gastroenterol 2003; 38: 681-686
    CrossrefPubMedGoogle Scholar
  • 26 Reichmann H. View point: etiology in Parkinson’s disease. Dual hit or spreading intoxication. J Neurol Sci 2011; 310: 9-11
    CrossrefPubMedGoogle Scholar
  • 27 Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord 2012; 27: 597-607
    CrossrefPubMedGoogle Scholar
  • 28 Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 1995; 45: 669-671
    CrossrefPubMedGoogle Scholar
  • 29 Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Neurology 1996; 47 (Suppl. 03) S146-S152
    CrossrefPubMedGoogle Scholar
  • 30 Hely MA, Morris JG, Reid WG et al. Age at onset: the major determinant of outcome in Parkinson’s disease. Acta Neurol Scand 1995; 92: 455-463
    PubMedGoogle Scholar
  • 31 Doty RL, Golbe LI, McKeown DA et al. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson’s disease. Neurology 1993; 43: 962-965
    CrossrefPubMedGoogle Scholar
  • 32 Puschmann A. Monogenic Parkinson’s disease and parkinsonism: Clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013; 19: 407-415
    CrossrefPubMedGoogle Scholar
  • 33 Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov Disord 2011; 26: 1042-1048
    CrossrefPubMedGoogle Scholar
  • 34 Gomez Arevalo G, Jorge R, Garcia S et al. Clinical and pharmacological differences in early- versus late-onset Parkinson’s disease. Mov Disord 1997; 12: 277-284
    CrossrefPubMedGoogle Scholar
  • 35 Kostic V, Przedborski S, Flaster E et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 1991; 41: 202-205
    CrossrefPubMedGoogle Scholar
  • 36 Wickremaratchi MM, Knipe MD, Sastry BS et al. The motor phenotype of Parkinson’s disease in relation to age at onset. Mov Disord 2011; 26: 457-463
    CrossrefPubMedGoogle Scholar
  • 37 Healy DG, Falchi M, O’Sullivan SS et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 2008; 7: 583-590
    CrossrefPubMedGoogle Scholar
  • 38 Kagi G, Klein C, Wood NW et al. Nonmotor symptoms in Parkin gene-related parkinsonism. Mov Disord 2010; 25: 1279-1284
    CrossrefPubMedGoogle Scholar
  • 39 Schrag A, Ben-Shlomo Y, Brown R et al. Young-onset Parkinson’s disease revisited – clinical features, natural history, and mortality. Mov Disord 1998; 13: 885-894
    CrossrefPubMedGoogle Scholar
  • 40 Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 2011; 91: 1161-1218
    CrossrefPubMedGoogle Scholar
  • 41 Lill CM, Roehr JT, McQueen MB et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson’s disease genetics: The PDGene database. PLoS Genet 2012; 8: e1002548
    CrossrefPubMedGoogle Scholar
  • 42 Xiang W, Schlachetzki JC, Bussmann J et al. Oxidative stress-induced posttranslational modifications of alpha-synuclein: Specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol Cell Neurosci 2013; 54: 71-83
    CrossrefPubMedGoogle Scholar
  • 43 Spillantini MG, Schmidt ML, Lee VM et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840
    CrossrefPubMedGoogle Scholar
  • 44 Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998; 4: 1318-1320
    CrossrefPubMedGoogle Scholar
  • 45 Klucken J, Ingelsson M, Shin Y et al. Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol 2006; 111: 101-108
    CrossrefPubMedGoogle Scholar
  • 46 Olanow CW, Perl DP, DeMartino GN et al. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004; 3: 496-503
    CrossrefPubMedGoogle Scholar
  • 47 Winner B, Jappelli R, Maji SK et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 2011; 108: 4194-4199
    CrossrefPubMedGoogle Scholar
  • 48 Klucken J, Poehler AM, Ebrahimi-Fakhari D et al. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 2012; 8: 754-766
    CrossrefPubMedGoogle Scholar
  • 49 Dunning CJ, George S, Brundin P. What’s to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease?. Prion 2013; 7: 92-97
    CrossrefPubMedGoogle Scholar
  • 50 El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. Faseb J 2006; 20: 419-425
    CrossrefPubMedGoogle Scholar
  • 51 Braak H, Bohl JR, Muller CM et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 2006; 21: 2042-2051
    CrossrefPubMedGoogle Scholar
  • 52 Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211
    CrossrefPubMedGoogle Scholar
  • 53 Shannon KM, Keshavarzian A, Mutlu E et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord 2012; 27: 709-715
    CrossrefPubMedGoogle Scholar
  • 54 Braak H, de Vos RA, Bohl J et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006; 396: 67-72
    CrossrefPubMedGoogle Scholar
  • 55 Kalaitzakis ME, Graeber MB, Gentleman SM et al. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 2008; 34: 284-295
    CrossrefPubMedGoogle Scholar
  • 56 Halliday G, Lees A, Stern M. Milestones in Parkinson’s disease – clinical and pathologic features. Mov Disord 2011; 26: 1015-1021
    CrossrefPubMedGoogle Scholar
  • 57 Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 2008; 64: 485-491
    CrossrefPubMedGoogle Scholar
  • 58 Burke RE, O’Malley K. Axon degeneration in Parkinson’s disease. Exp Neurol 2012; 246: 72-83
    PubMedGoogle Scholar
  • 59 Selikhova M, Williams DR, Kempster PA et al. A clinico-pathological study of subtypes in Parkinson’s disease. Brain 2009; 132: 2947-2957
    CrossrefPubMedGoogle Scholar
  • 60 Parkkinen L, Kauppinen T, Pirttila T et al. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005; 57: 82-91
    CrossrefPubMedGoogle Scholar
  • 61 Jellinger KA. Formation and development of Lewy pathology: a critical update. J Neurol 2009; 256 (Suppl. 03) 270-279
    CrossrefPubMedGoogle Scholar
  • 62 Parkkinen L, Silveira-Moriyama L, Holton JL et al. Can olfactory bulb biopsy be justified for the diagnosis of Parkinson’s disease? Comments on “olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders”. Acta Neuropathol 2009; 117: 213-214; author reply 217 – 218
    CrossrefPubMedGoogle Scholar
  • 63 Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399-407
    CrossrefPubMedGoogle Scholar
  • 64 Beach TG, Adler CH, Sue LI et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689-702
    CrossrefPubMedGoogle Scholar
  • 65 Alafuzoff I, Ince PG, Arzberger T et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009; 117: 635-652
    CrossrefPubMedGoogle Scholar
  • 66 Li JY, Englund E, Holton JL et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503
    CrossrefPubMedGoogle Scholar
  • 67 Kordower JH, Chu Y, Hauser RA et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 2008; 14: 504-506
    CrossrefPubMedGoogle Scholar
  • 68 Brundin P, Li JY, Holton JL et al. Research in motion: the enigma of Parkinson’s disease pathology spread. Nat Rev Neurosci 2008; 9: 741-745
    CrossrefPubMedGoogle Scholar
  • 69 El-Agnaf OM, Salem SA, Paleologo KE et al. Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 2003; 17: 1945-1947
    PubMedGoogle Scholar
  • 70 Emmanouilidou E, Melachroinou K, Roumeliotis T et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010; 30: 6838-6851
    CrossrefPubMedGoogle Scholar
  • 71 Freundt EC, Maynard N, Clancy EK et al. Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Ann Neurol 2012; 72: 517-524
    CrossrefPubMedGoogle Scholar
  • 72 Alvarez-Erviti L, Seow Y, Schapira AH et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011; 42: 360-367
    CrossrefPubMedGoogle Scholar
  • 73 Hansen C, Angot E, Bergstrom AL et al. Alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-725
    CrossrefPubMedGoogle Scholar
  • 74 Lee HJ, Suk JE, Bae EJ et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008; 40: 1835-1849
    CrossrefPubMedGoogle Scholar
  • 75 Danzer KM, Ruf WP, Putcha P et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. Faseb J 2011; 25: 326-336
    CrossrefPubMedGoogle Scholar
  • 76 Desplats P, Lee HJ, Bae EJ et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-13015
    CrossrefPubMedGoogle Scholar
  • 77 Diogenes MJ, Dias RB, Rombo DM et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012; 32: 11750-11762
    CrossrefPubMedGoogle Scholar
  • 78 Hilker R, Brotchie JM, Chapman J. Pros and cons of a prion-like pathogenesis in Parkinson’s disease. BMC Neurol 2011; 11: 74
    CrossrefPubMedGoogle Scholar
  • 79 Luk KC, Song C, O’Brien P et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009; 106: 20051-20056
    CrossrefPubMedGoogle Scholar
  • 80 Steiner JA, Angot E, Brundin P. A deadly spread: cellular mechanisms of alpha-synuclein transfer. Cell Death Differ 2011; 18: 1425-1433
    CrossrefPubMedGoogle Scholar
  • 81 Luk KC, Kehm V, Carroll J et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-953
    CrossrefPubMedGoogle Scholar
  • 82 Luk KC, Kehm VM, Zhang B et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 2012; 209: 975-986
    CrossrefPubMedGoogle Scholar
  • 83 Pan-Montojo F, Anichtchik O, Dening Y et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 2010; 5: e8762
    CrossrefPubMedGoogle Scholar
  • 84 Pan-Montojo F, Schwarz M, Winkler C et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012; 2: 898
    PubMedGoogle Scholar
  • 85 Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10: 230-240
    CrossrefPubMedGoogle Scholar
  • 86 Lee PH, Lee G, Park HJ et al. The plasma alpha-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J Neural Transm 2006; 113: 1435-1439
    CrossrefPubMedGoogle Scholar
  • 87 Lebouvier T, Coron E, Chaumette T et al. Routine colonic biopsies as a new tool to study the enteric nervous system in living patients. Neurogastroenterol Motil 2010; 22: e11-14
    PubMedGoogle Scholar
  • 88 Postuma RB, Aarsland D, Barone P et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27: 617-626
    CrossrefPubMedGoogle Scholar
  • 89 Meusel T, Westermann B, Fuhr P et al. The course of olfactory deficits in patients with Parkinson’s disease – a study based on psychophysical and electrophysiological measures. Neurosci Lett 2010; 486: 166-170
    CrossrefPubMedGoogle Scholar
  • 90 Haehner A, Hummel T, Reichmann H. Olfactory dysfunction as a diagnostic marker for Parkinson’s disease. Expert Rev Neurother 2009; 9: 1773-1779
    CrossrefPubMedGoogle Scholar
  • 91 Behnke S, Schroder U, Berg D. Transcranial sonography in the premotor diagnosis of Parkinson’s disease. Int Rev Neurobiol 2010; 90: 93-106
    PubMedGoogle Scholar
  • 92 van de Loo S, Walter U, Behnke S et al. Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2010; 81: 1087-1092
    CrossrefPubMedGoogle Scholar
  • 93 Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson’s disease. Neuron 2005; 46: 857-868
    CrossrefPubMedGoogle Scholar
  • 94 Reynolds AD, Stone DK, Hutter JA et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 2010; 184: 2261-2271
    CrossrefPubMedGoogle Scholar
  • 95 Bae EJ, Lee HJ, Rockenstein E et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012; 32: 13454-13469
    CrossrefPubMedGoogle Scholar
  • 96 Masliah E, Rockenstein E, Mante M et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011; 6: e19338
    CrossrefPubMedGoogle Scholar